Who is sponsoring NCT07390214?

NCT07390214 is sponsored by Cardioangiologisches Centrum Bethanien.

What condition does NCT07390214 study?

NCT07390214 studies Atrial Fibrillation - Symptomatic.

Is NCT07390214 still recruiting?

NCT07390214 is currently recruiting now. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT07390214: REFOCUS-AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REFOCUS-AF - "RepEat Ablation With AFFERA vs. COntact Force-Guided RF Catheters for Optimal OUtcomes in Symptomatic AF".

Recruiting now NA Last updated 5 February 2026

What this trial tests

NA trial testing Dual Energy ablation with RF/PFA: Re-PVI and substrate modification of low voltage areas in Atrial Fibrillation - Symptomatic in 200 participants. Currently enrolling.

Timeline

15 December 2025

Primary endpoint
30 June 2028

30 March 2029

Quick facts

Lead sponsor	Cardioangiologisches Centrum Bethanien
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	15 December 2025
Primary completion	30 June 2028
Estimated completion	30 March 2029
Sites	1 location across Germany

Drugs / interventions tested

Dual Energy ablation with RF/PFA: Re-PVI and substrate modification of low voltage areas
CF-guided RFC: Re-PVI and substrate modification of low voltage areas

Conditions studied

Atrial Fibrillation - Symptomatic — all drugs for Atrial Fibrillation - Symptomatic →

Sponsor

Cardioangiologisches Centrum Bethanien

Who can join

Adults 18 to 85, any sex, with Atrial Fibrillation - Symptomatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized (1:1), pilot study enrolling 200 patients with symptomatic atrial fibrillation or atrial tachycardia (AF/AT) recurrence requiring repeat ablation following a single prior PVI procedure for AF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation - Symptomatic

Currently open trials in the same condition.

NCT03355456 — Low Voltage-Directed Catheter Ablation for Atrial Fibrillation · NA · recruiting

Other Cardioangiologisches Centrum Bethanien trials

Trials by the same sponsor.

NCT07459387 — REal-world Valued Outcomes of a noveL Balloon-in-basket pUlsed Field ablaTION Catheter for Atrial Fibrillation RegistrY · NA · recruiting
NCT06403527 — Ultrasound Guyded Venous Puncture for Safe AF Ablation Procedures · NA · terminated
NCT07385417 — Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study · NA · recruiting
NCT05313048 — Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vacci · completed
NCT05823818 — EUropean Real World Outcomes With Pulsed Field AblatiOn · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07390214 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardioangiologisches Centrum Bethanien
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07390214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing